Addentax Group Corp. — Form 8-K Summary
Business context and reporting period
The report is dated September 30, 2026. It reports a material definitive agreement and an unregistered equity issuance; it does not provide quarterly or annual operating results.
Transaction and key financial terms
- On September 28, 2026, the Company agreed to sell 520,834 shares of common stock to Chan Kai Sang at $4.80 per share.
- Expected gross proceeds are approximately $2.5 million. Net proceeds are intended for general corporate purposes, including working capital and potential strategic investments.
- The filing provides no revenue, profit, cash flow, margin, debt, or liquidity figures.
Material changes, conditions, and risks
The planned share issuance will increase the number of outstanding shares, but the filing does not state the existing share count or quantify dilution. Closing is subject to customary conditions, which may be satisfied or waived. The shares are expected to be issued under Regulation S in an offshore transaction to an investor who is not a U.S. person; they will be unregistered and carry restrictive legends.
The filing gives no broader business outlook or management commentary. The transaction’s completion and the amount of net proceeds are not confirmed.
Key facts for investors to verify
- Whether the private placement closed and the shares were issued.
- Actual proceeds after expenses and their use.
- Resulting share count and dilution to existing shareholders.
- Full terms and closing conditions in the Private Placement Agreement filed as Exhibit 10.1.